Company intelligence / Profile preview

Eppin Pharma

Durham, North Carolina, United Stateseppinpharmainc.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Eppin Pharma's lead candidate EP055 is a small organic compound that binds to EPPIN protein on sperm, resulting in loss of sperm motility. The company has completed a successful proof-of-concept study in primates at the Oregon National Primate Research Center in April 2018 and is preparing for human clinical trials[2][6].

Therapeutic areas: Men's Health
Modalities: Small organic compounds
Industry: Biotech

Drug pipeline

2 assets

EP055

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

Male Contraceptive Initiative (MCI)

Beyond the preview

Go deeper on Eppin Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eppin Pharma.

Explore the full profile